Nidal İFLAZOĞLU, Kıvılcım EREN ERDOĞAN, Ali DURAN, Emir ÇAPKINOĞLU, Cem Kaan PARSAK, Figen DORAN

Sentinel lymph node dissection in colorectal cancers: A single-center, prospective study

Aim: In this study, we aimed to investigate the feasibility of ex vivosentinel lymph node (SLN) mapping and to evaluate efficacy ofthis technique on staging in patients with colorectal cancer.Material and Methods: : This single-center, prospective study included a total of 35 patients (25 males, 10 females; mean age: 55years; range, 35 to 85 years) who were diagnosed with Stage 2 colorectal cancer between May 2015 and August 2017. All patientsunderwent curative surgery and SLN dissection.Results: Tumor was located in rectum in 17, in sigmoid colon in six, in right colon in seven, and in left colon in five patients. Totalabdominal colectomy was performed in six, left hemicolectomy in three, right hemicolectomy in six, low anterior resection in 14,anterior resection in two, and abdominoperineal resection in four patients. Of 17 patients with clinical Stage 2 rectal cancer, 15underwent neoadjuvant chemoradiotherapy (CRT). All patients were histopathologically diagnosed with an adenocarcinoma.Median total number of SLNs dissected was 13 with 16.9 per patient. In two patients receiving neoadjuvant CRT due to rectalcancer, a pathological complete response was achieved. The failure rate of SLNs detection was statistically significantlyhigher for rectal tumors than the other tumors (p=0.041) and in the patients in whom ≤7 lymph nodes dissected (p=0.023).Conclusion: Our study results suggest that SLN mapping is a useful technique with high success ratesas well as furtherimmunohistochemical examination of the SLNs doesn’t cause stage migration. However, the success rate is lower in rectal tumorsthan the other tumors and in the patients with ≤7 lymph nodes dissected.

PDF

___

1. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: colon and rectum cancer. http://seer.cancer.gov/statfacts/ html/colorect.html. Accessed April 17, 2019.
2. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008;3:CD005390.
3. Oh SY, Kim do Y, Kim YB, et al. Clinical application of sentinel lymph node mapping in colon cancer: in vivo vs. ex vivo techniques. Ann Surg Treat Res,2014;87:118-22.
4. Sfeclan MC, Vilcea ID, Barisic G, et al. The sentinel lymph node (SLN) significance in colorectal cancer: methods and results. General report. Rom J MorpholEmbryol 2015;56:943-7.
5. https://www.nccn.org/professionals/physician_gls/ pdf/colon.pdf (last entrance: 04.07.2019)
6. Cohen AM, Kelsen D, Saltz L, et al. Adjuvant therapy for colorectal cancer. CurrProblSurg 1997;34:601-76.
7. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel protocol C-03. J ClinOncol 1993;11:1879-87.
8. van der Zaag ES, Bouma WH, Tanis PJ, et al. Systematic review of sentinel lymph node mapping procedure in colorectal cancer. Ann SurgOncol 2012;19:3449-59.
9. Mogoanta SS, Calota F, Vasile I, et al. Histological and immunohistochemical study on sentinel lymph node in colorectal cancer - values and limitations. Rom J MorpholEmbryol 2016;57:65-74.
10. Bertagnolli M, Miedema B, Redston M, et al. Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg 2004;240:624-30.
11. Merrie AE, van Rij AM, Phillips LV, et al. Diagnostic use of the sentinel node in colon cancer. Dis Colon Rectum 2001;44:410-7.
12. Tsioulias GJ, Wood TF, Morton DL, et al. Lymphatic mapping and focused analysis of sentinel lymph nodes upstage gastrointestinal neoplasms. Arch Surg 2000;135:926-32.
13. Wang FL, Shen F, Wan DS, et al. Ex vivo localization and immunohistochemical detection of sentinel lymph node micrometastasis in patients with colorectal cancer can upgrade tumor staging. DiagnPathol 2012;7:71.
14. Khafagy W, El-Dawoody A, El-Ghawalby N, et al. Ultrastaging of rectal cancer based on identification of micrometastases in sentinel lymph node. Coloproctology 2005; 27:153-60.
15. van der Zaag ES, Bouma WH, Peters HM, et al. Implications of sentinel lymph node mapping on nodal staging and prognosis in colorectal cancer. Colorectal Dis 2012;14:684-90.
16. Finan KR, Lewis JS Jr, Winslow E, et al. Ex vivo sentinel lymph node mapping in patients undergoing proctectomy for rectal cancer. Dis Colon Rectum 2010;53:243-50.
17. Han J, Noh GT, Yeo SA, Cheong C, Cho MS, Hur H, et al. The number of retrieved lymph nodes needed for accurate staging differs based on the presence of preoperative chemoradiation for rectal cancer. Medicine (Baltimore). 2016;95:4891.
18. Nissan A, Protic M, Bilchik AJ, et al. United States Military Cancer Institute Clinical Trials Group (USMCI GI-01) randomized controlled trial comparing targeted nodal assessment and ultrastaging with standard pathological evaluation for colon cancer. Ann Surg 2012;256:412-27.
19. Cleothoak DA, Sahami S, Vander Zaag-Lounen HJ, et al. The prognostic value of micrometastasis and isolated tumor cells in histologically negative lymph nodes of patients with colorectal cancer: a systematic review and meta-analysis. European J Surgical Oncology 2014;40:263-9
20. Protic M, Stojadinovic A, Nissan A, et al. Prognostic effect of ultra-staging node negative colon cancer without adjuvant therapy. A Prospective National Cancer Institue-Sponsored clinical trial. The Journal of American Collage of Surgeons 2015;221:631-43
21. Pallares-Segura JL, Balague-Pons C, DominguezAgustin N, et al. The role of sentinel lymph node in colon cancer evolution. Cir Esp 2014;92:670-5.
22. Bembenek A, Rau B, Moesta T, et al. Sentinel lymph node biopsy in rectal cancer--not yet ready for routine clinical use.Surgery 2004;135:498-507.